Advertisement

Hormones

, Volume 18, Issue 1, pp 55–63 | Cite as

Hypoparathyroidism: is it that easy to treat?

  • Evangelia Triantafyllou
  • Maria P. Yavropoulou
  • Athanasios D. Anastasilakis
  • Polyzois MakrasEmail author
Review Article

Abstract

Hypoparathyroidism is a relatively rare endocrine disease characterised by either null or inappropriately low secretion of parathyroid hormone (PTH) for serum calcium levels. The other main laboratory findings include hypocalcaemia, inappropriately normal or high urine calcium excretion and hyperphosphataemia with low urine phosphate excretion. The management of hypoparathyroidism should be tailored to each individual case, which makes it a demanding undertaking in everyday clinical practice. In this review, we sought to focus on the diagnostic approach of hypoparathyroidism and the therapeutic challenges of the disease from a clinical perspective. Conventional treatment with vitamin D analogues and calcium salts is no longer the only available treatment, since replacement treatment with PTH(1-84) has recently been approved for the disease. However, the optimal treatment schedule is yet to be defined.

Keywords

Hypoparathyroidism Calcium PTH1-34 PTH1-84 

Notes

Compliance with ethical standards

Conflict of interest

All authors have nothing to declare regarding this paper.

References

  1. 1.
    Cooper MS, Gittoes NJ (2008) Diagnosis and management of hypocalcaemia. BMJ 336:1298–1302CrossRefGoogle Scholar
  2. 2.
    Abate EG, Clarke BL (2016) Review of hypoparathyroidism. Front Endocrinol (Lausanne) 7:172Google Scholar
  3. 3.
    Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D et al (2011) Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 26:2317–2337CrossRefGoogle Scholar
  4. 4.
    Powers J, Joy K, Ruscio A, Lagast H (2013) Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res 28:2570–2576CrossRefGoogle Scholar
  5. 5.
    Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB et al (2012) Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 97:4507–4514CrossRefGoogle Scholar
  6. 6.
    Garrahy A, Murphy MS, Sheahan P (2016) Impact of postoperative magnesium levels on early hypocalcemia and permanent hypoparathyroidism after thyroidectomy. Head Neck 38:613–619CrossRefGoogle Scholar
  7. 7.
    Nakamoto JM, Sandstrom AT, Brickman AS, Christenson RA, Van Dop C (1998) Pseudohypoparathyroidism type Ia from maternal but not paternal transmission of a Gsalpha gene mutation. Am J Med Genet 77:261–267CrossRefGoogle Scholar
  8. 8.
    Stieler K, Schnabel D, Atugoda S, Sterry W, Blume-Peytavi U (2011) Albright hereditary osteodystrophy. Pediatr Dermatol 28:135–137CrossRefGoogle Scholar
  9. 9.
    Elli FM, deSanctis L, Ceoloni B, Barbieri AM, Bordogna P, Beck-Peccoz P, Spada A, Mantovani G (2013) Pseudohypoparathyroidism type Ia and pseudo-pseudohypoparathyroidism: the growing spectrum of GNAS inactivating mutations. Hum Mutat 34:411–416CrossRefGoogle Scholar
  10. 10.
    Shoback D (2008) Clinical practice: hypoparathyroidism. N Engl J Med 359:391–403CrossRefGoogle Scholar
  11. 11.
    Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, Khan AA et al (2016) Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab 101:2300–2312CrossRefGoogle Scholar
  12. 12.
    Rastogi R, Beauchamp NJ, Ladenson PW (2003) Calcification of the basal ganglia in chronic hypoparathyroidism. J Clin Endocrinol Metab 88:1476–1477CrossRefGoogle Scholar
  13. 13.
    Preusser M, Kitzwoegerer M, Budka H, Brugger S (2007) Bilateral striopallidodentate calcification (Fahr's syndrome) and multiple system atrophy in a patient with longstanding hypoparathyroidism. Neuropathology 27:453–456CrossRefGoogle Scholar
  14. 14.
    Cakerri L, Husi G, Minxuri D, Roko E, Vyshka G (2014) Primary hypoparathyroidism presenting with heart failure and ventricular fibrillation. Oxf Med Case Reports 4:77–79Google Scholar
  15. 15.
    Rubin MR, Dempster DW, Kohler T, Stauber M, Zhou H, Shane E et al (2010) Three dimensional cancellous bone structure in hypoparathyroidism. Bone 46:190–195CrossRefGoogle Scholar
  16. 16.
    Rubin MR, Bilezikian JP (2010) Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. Arq Bras Endocrinol Metabol 54:220–226CrossRefGoogle Scholar
  17. 17.
    Cusano NE, Nishiyama KK, Zhang C, Rubin MR, Boutroy S, McMahon DJ et al (2016) Noninvasive assessment of skeletal microstructure and estimated bone strength in hypoparathyroidism. J Bone Miner Res 31:308–316CrossRefGoogle Scholar
  18. 18.
    Christen P, Ito K, Muller R, Rubin MR, Dempster DW, Bilezikian JP et al (2012) Patient-specific bone modelling and remodelling simulation of hypoparathyroidism based on human iliac crest biopsies. J Biomech 45:2411–2416CrossRefGoogle Scholar
  19. 19.
    Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2015) The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res 30:1738–1744CrossRefGoogle Scholar
  20. 20.
    Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2014) Postsurgical hypoparathyroidism—risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res 29:2504–2510CrossRefGoogle Scholar
  21. 21.
    Mendonca ML, Pereira FA, Nogueira-Barbosa MH, Monsignore LM, Teixeira SR, Watanabe PC et al (2013) Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr Disord 13:1CrossRefGoogle Scholar
  22. 22.
    Buttner M, Musholt TJ, Singer S (2017) Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review. Endocrine 58:14–20CrossRefGoogle Scholar
  23. 23.
    Sikjaer T, Moser E, Rolighed L, Underbjerg L, Bislev LS, Mosekilde L, Rejnmark L (2016) Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism. J Bone Miner Res 31:1440–1448CrossRefGoogle Scholar
  24. 24.
    Rejnmark L (2018) Quality of life in hypoparathyroidism. Endocrine 59:237–238CrossRefGoogle Scholar
  25. 25.
    Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS et al (2012) Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab 97:391–399CrossRefGoogle Scholar
  26. 26.
    Thakker RVBF, Jόppner H (2016) Regulation of calcium homeostasis and genetic disorders that affect calcium metabolism. Elsevier, PhiladelphiaGoogle Scholar
  27. 27.
    Hannan FM, Thakker RV (2013) Investigating hypocalcaemia. BMJ 346:f2213CrossRefGoogle Scholar
  28. 28.
    Akin L, Kurtoglu S, Yildiz A, Akin MA, Kendirici M (2010) Vitamin D deficiency rickets mimicking pseudohypoparathyroidism. J Clin Res Pediatr Endocrinol 2:173–175CrossRefGoogle Scholar
  29. 29.
    Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV et al (2016) Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab 101:2273–2283CrossRefGoogle Scholar
  30. 30.
    Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT Jr (2016) Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab 101:2313–2324CrossRefGoogle Scholar
  31. 31.
    Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W et al (2015) Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 173:G1–G20CrossRefGoogle Scholar
  32. 32.
    Stack BC Jr, Bimston DN, Bodenner DL, Brett EM, Dralle H, Orloff LA et al (2015) American Association of Clinical Endocrinologists and American College of Endocrinology Disease state clinical review: postoperative hypoparathyroidism—definitions and management. Endocr Pract 21:674–685CrossRefGoogle Scholar
  33. 33.
    Streeten EA, Mohtasebi Y, Konig M, Davidoff L, Ryan K (2017) Hypoparathyroidism: less severe hypocalcemia with treatment with vitamin D2 compared with calcitriol. J Clin Endocrinol Metab 102:1505–1510CrossRefGoogle Scholar
  34. 34.
    Spaia S (2011) Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure. Hippokratia 15:22–26Google Scholar
  35. 35.
    Winer KK, Yanovski JA, Cutler GB Jr (1996) Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 276:631–636CrossRefGoogle Scholar
  36. 36.
    Shah M, Bancos I, Thompson GB, Richards ML, Kasperbauer JL, Clarke BL et al (2015) Teriparatide therapy and reduced postoperative hospitalization for postsurgical hypoparathyroidism. JAMA Otolaryngol Head Neck Surg 141:822–827CrossRefGoogle Scholar
  37. 37.
    Palermo A, Santonati A, Tabacco G, Bosco D, Spada A, Pedone C et al (2018) PTH(1-34) for surgical hypoparathyroidism: a 2 year prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab 103:271–280CrossRefGoogle Scholar
  38. 38.
    Winer KK, Sinaii N, Peterson D, Sainz B Jr, Cutler GB Jr (2008) Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab 93:3389–3395CrossRefGoogle Scholar
  39. 39.
    Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr (2010) Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab 95:2680–2688CrossRefGoogle Scholar
  40. 40.
    Winer KK, Fulton KA, Albert PS, Cutler GB Jr (2014) Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J Pediatr 165:556–563 e551CrossRefGoogle Scholar
  41. 41.
    Clarke BL, Kay Berg J, Fox J, Cyran JA, Lagast H (2014) Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. Clin Ther 36:722–736CrossRefGoogle Scholar
  42. 42.
    Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG et al (2016) Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety. J Clin Endocrinol Metab 101:2742–2750CrossRefGoogle Scholar
  43. 43.
    Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD et al (2013) Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 1:275–283CrossRefGoogle Scholar
  44. 44.
    Clarke BL, Vokes TJ, Bilezikian JP, Shoback DM, Lagast H, Mannstadt M (2017) Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. Endocrine 55:273–282CrossRefGoogle Scholar
  45. 45.
    Misof BM, Roschger P, Dempster DW, Zhou H, Bilezikian JP, Klaushofer K et al (2016) PTH(1-84) administration in hypoparathyroidism transiently reduces bone matrix mineralization. J Bone Miner Res 31:180–189CrossRefGoogle Scholar
  46. 46.
    Lakatos P, Bajnok L, Lagast H, Valkusz Z (2016) An open-label extension study of parathyroid hormone Rhpth(1-84) in adults with hypoparathyroidism. Endocr Pract 22:523–532CrossRefGoogle Scholar
  47. 47.
    Bilezikian JP, Clarke BL, Mannstadt M, Rothman J, Vokes T, Lee HM et al (2017) Safety and efficacy of recombinant human parathyroid hormone in adults with hypoparathyroidism randomly assigned to receive fixed 25-mug or 50-mug daily doses. Clin Ther 39:2096–2102CrossRefGoogle Scholar
  48. 48.
    Cusano NE, Rubin MR, McMahon DJ, Irani D, Anderson L, Levy E et al (2014) PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab 99:3694–3699CrossRefGoogle Scholar
  49. 49.
    Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L (2014) Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int 25:1717–1726CrossRefGoogle Scholar
  50. 50.
    Santonati A, Palermo A, Maddaloni E, Bosco D, Spada A, Grimaldi F et al (2015) PTH(1-34) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab 100:3590–3597CrossRefGoogle Scholar
  51. 51.
    Theman TA, Collins MT, Dempster DW, Zhou H, Reynolds JC, Brahim JS et al (2009) PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. J Bone Miner Res 24:964–973CrossRefGoogle Scholar
  52. 52.
    Cusano NE, Rubin MR, McMahon DJ, Zhang C, Ives R, Tulley A et al (2013) Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab 98:137–144CrossRefGoogle Scholar
  53. 53.
    Clarke BV, Vokes TJ, Bilezikian JP (2017) Recombinant human parathyroid hormone (rhPTH[1-84], parathyroid hormone rDNA) improves hypercalciuria in patients with hypoparathyroidism: 3-year analysis from RACE study. Endocr Abstr 49:GP47Google Scholar
  54. 54.
    Levine MB, Sundberg JP, Clarke, BL. (2015) Long-Term effects of recombinant human parathyroid hormone, rhPTH(1-84), on bone remodeling in patients with hypoparathyroidism: 3-year data from the open-label RACE study. In ECTS and IBMS joined meeting. RotterdamGoogle Scholar
  55. 55.
    Cipriani C, Irani D, Bilezikian JP (2012) Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 27:2419–2428CrossRefGoogle Scholar
  56. 56.
    Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH et al (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27:2429–2437CrossRefGoogle Scholar
  57. 57.
    Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531–1543CrossRefGoogle Scholar
  58. 58.
    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA et al (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321CrossRefGoogle Scholar
  59. 59.
    Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ et al (2006) Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 34:929–940CrossRefGoogle Scholar
  60. 60.
    Bilezikian JP, Drezner M, Kream B, Stern P, Clemens T, Elderkin A et al (2011) Lawrence G. Raisz November 13, 1925-August 25, 2010. J Bone Miner Res 26:903–911CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2018

Authors and Affiliations

  • Evangelia Triantafyllou
    • 1
  • Maria P. Yavropoulou
    • 1
  • Athanasios D. Anastasilakis
    • 2
  • Polyzois Makras
    • 3
    Email author
  1. 1.Division of Endocrinology and Metabolism, 1st Department of Internal Medicine, AHEPA University HospitalAristotle University of ThessalonikiThessalonikiGreece
  2. 2.Department of Endocrinology424 General Military HospitalThessalonikiGreece
  3. 3.Department of Endocrinology and Diabetes251 Hellenic Air Force & VA General HospitalAthensGreece

Personalised recommendations